Vanguard Amends 13G: Reports 0 DXCM Shares
Dexcom Inc ownership filing: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Dexcom common stock, representing 0% of the class.
Rhea-AI Filing Summary
Dexcom Inc ownership filing: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Dexcom common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will report disaggregated beneficial ownership.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
Vanguard's amendment states 0 shares beneficially owned and 0% of the class. The filing cites the January 12, 2026 realignment and SEC Release No. 34-39538 as the basis for disaggregated reporting.
Cash-flow treatment and any holdings now reported by subsidiary entities are not detailed in this excerpt; subsequent filings by the individual subsidiaries may show the redistributed positions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Vanguard report for DXCM ownership in this 13G/A amendment?
Why does The Vanguard Group report zero ownership for DXCM?
Are any other persons shown as having more than 5% of DXCM in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.